Global business opens Focus on innovative technology platforms and key disease areas to build core competitiveness
Innovent Biologics’ innovative R&D engine, Guoqing Institute, has built a comprehensive technology
platform, including ScFv engineering, T cell country email list connector (TCE, VHH bispecific antibodies, Topo1i ADC,
dualload ADC, antibodypeptide conjugates (APC and other innovative technologies, which can
efficiently and continuously produce innovative molecules sometimes visuals can help and provide a source of power for the company’s longterm development.
Among them, Innovent Biologics has combin worldleading antibody engineering and multiple sets of
differentiat linkerpayload technologies to create a highly competitive innovative TOPO1i ADC
technology platform and dualpayload ADC technology platform, and has efficiently produc a new generation of potential bestinclass (BIC or firstinclass (FIC ADC drug candidates.
To date, the company has
ADC drug candidates entering clinical research, and has accumulat efficacy and safety data from more
than 600 patients. Multiple ADC molecules have obtain breakthrough therapy designation (BTD, fully
validating the advanc nature of the company’s ADC platform technology and its consistent clinical execution capabilities.
The company continues to focus on core highpotential disease areas, and continues to strengthen its
leadership in the field of oncology through a rich and trust review powerful product pipeline of “PD1+precision
therapy”. Under the new generation of “IO+ADC” strategy, breakthroughs in innovative therapies are
expect to bring about changes in cancer treatment. At the same time, the company’s comprehensive
pipeline covers autoimmunity, cardiovascular and metabolic, ophthalmology, etc. The new generation
of innovative drugs will improve treatment standards for a wide range of disease populations.
Guoqing Institute has been preparing for many years
An the new generation of pipelines has usher in new opportunities for global development. Innovative
pipelines represent by the new generation of IO and ADC are ushering in new global development
opportunities. In the future, more innovative ADCs, bispecific (multispecific antibodies, nextgeneration autoimmune and CVM pipelines will gradually enter global development Global business opens.